Using AI to Generate Mini-Protein Therapeutics

David Longo, co-founder and CEO of Ordaōs, discusses the company’s focus on mini-proteins, its generative AI platform, and why its building its own pipeline around rare disease indications and partnering with other drug developers on other indications.